19 December 2017 - - Two of San Diego, California-based non-prescription medicine and consumer care products company Innovus Pharmaceuticals, Inc.'s (OTCQB Venture Market: INNV) products, FlutiCare for nasal allergy relief and UriVarx for bladder health, have been approved for listing in the over-the-counter (OTC) section of the Red Book pharmacy pricing database, the company said.
Red Book provides the latest pricing and product information on prescription and over-the-counter drug products within the industry, enabling healthcare professionals to quickly answer drug-related questions with information for 200,000+ prescription and over-the-counter drugs, nutraceuticals, and bulk chemicals.
The Red Book serves as a resource for drug utilization reviews, market analysis and research, prescription pricing, and order entry. It establishes and validates reimbursement, forecasting, drug-pricing research, generic substitution, therapeutic interchange, competitive analysis, purchasing, forumulary development and management, as well as claims adjudication, processing and validation.
FlutiCare is Innovus' nationally branded OTC fluticasone propionate nasal spray, USP 50 mcg per spray, which is indicated to treat individuals with allergic rhinitis.
UriVarx targets the bladder and surrounding tissues to promote normal urination and strong bladder tone, and is clinically proven in an 8-week double blind placebo controlled clinical trial in 150 patients to support bladder tone and function.
Innovus Pharma is engaged in the commercialisation, licensing, and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality, and respiratory diseases.